Disclosures for "Baseline Characteristics and Preliminary Safety from a Multicenter, Safety Surveillance Study of Lecanemab Treatment for Alzheimer’s Disease in Real-world Clinical Practice Using Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) Registry"
-
Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alzheon. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche-Genentech. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Sabbagh has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for EIP Pharma.
-
Dr. Cornelissen has nothing to disclose.
-
Dr. Michael has nothing to disclose.
-
Dr. Surick has received personal compensation for serving as an employee of Eisai Inc.
-
Shobha Dhadda has received personal compensation for serving as an employee of Eisai Inc.
-
Mr. Kanekiyo has received personal compensation for serving as an employee of Eisai Inc. Mr. Kanekiyo has stock in Eisai Co Ltd..
-
Dr. Hersch has received personal compensation for serving as an employee of Eisai Inc.. Dr. Hersch has stock in Voyager Therapeutics. The institution of an immediate family member of Dr. Hersch has received research support from NIH. Dr. Hersch has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Irizarry has received personal compensation for serving as an employee of Eisai, Inc..